No need to suffer heartburn after a heart attack
This article was originally published in Pharmaceutical Approvals Monthly
Although proton pump inhibitors do have a negative influence on the antiplatelet effects of clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) and prasugrel (Lilly/Daiichi Sankyo's Effient), the antacids don't appear to interfere with the clinical outcome for patients, according to an analysis of data from the TIMI-44 and TIMI-38 trials presented Sept. 1 at the European Society of Cardiology congress. The antacids are thought to inhibit the conversion of the thienopyridine class drugs into active form in the body, and the drug-drug interaction has sparked safety warnings from both FDA and EMEA. Professional guidelines, however, still recommend administering PPIs with the antiplatelet drugs to help reduce the risk of gastrointestinal bleeding. AstraZeneca's experimental antiplatelet drug Brilinta (ticagrelor), for which positive Phase III data was presented at ESC, may offer a solution to the interaction dilemma if it is approved as anticipated in 2010. Ticagrelor has a different mechanism of action from clopidogrel or prasugrel; it is an active compound that does not require bioactivation (1"The Pink Sheet," Sept. 7, 2009)
You may also be interested in...
The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.